Ignelzi has more than 25 years of experience supporting life science companies in finance, business development and operations, and has helped oversee their evolutions from privately held, clinical-stage companies to publicly traded biopharmaceutical companies preparing for commercial launches.
Ignelzi has played a key role in seven IPOs, and currently serves as the chief financial officer of Karuna Therapeutics.
He joined Karuna in March 2019, coming from scPharmaceuticals, where he was also in the role of chief financial officer, overseeing its transformation to a company preparing for commercial launch.
Prior to scPharmaceuticals, Ignelzi was a senior executive at Juventas Therapeutics, Esperion Therapeutics and Insys Therapeutics, helping raise public and private capital, expand development pipelines through licensing and acquisition and advancing critical therapies, several of which are currently approved by the US Food and Drug Administration.
Ignelzi holds a B.A. in accounting from Ferris State University.
Vedanta Biosciences is leading the development of a potential new category of oral therapies based on rationally defined consortia of bacteria derived from the human microbiome.
The company's clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy.
These investigational therapies are grounded in pioneering research published in leading journals including Science, Nature, and Cell to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens and induce a range of potent immune responses.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007